Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020095113 - HUMANIZED AND VARIANT TGF-BETA1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF

Publication Number WO/2020/095113
Publication Date 14.05.2020
International Application No. PCT/IB2019/001229
International Filing Date 04.11.2019
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/22 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors ; ; against growth regulators
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/56
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
C07K 2317/565
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
565Complementarity determining region [CDR]
Applicants
  • LUDWIG INSTITUTE FOR CANCER RESEARCH LTD [CH]/[CH]
  • CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS [CH]/[CH]
Inventors
  • RITTER, Gerd
  • DUNN, Steven
Priority Data
62/755,87905.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HUMANIZED AND VARIANT TGF-BETA1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
(FR) ANTICORPS SPÉCIFIQUES DE TGF-BÊTA1 ET PROCÉDÉS ET UTILISATIONS ASSOCIÉS
Abstract
(EN)
Antibodies, particularly humanized and variant antibodies and fragments thereof, which bind to TGF-β1 are provided, recognizing human and mouse TGF-β1, particularly that preferentially bind TGF-β1, including which do not recognize or bind ΤΟΡ-β2 or ΤΟΡ-β3. Humanized and variant antibodies provided are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens, and in fibrotic conditions. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in lymphoid cell-mediated, including T cell-mediated, therapy and/or combination with chemotherapeutic s, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Particular antibodies are exemplified herein, including antibodies 13A1-2A, 13A1-2B, 13A1-2C, 13A1-2D, 13A1-2E, 13A1-2F, 13A1-2G, 13A1-2H, 13A1-2I, 13A1-2J, 13A1-AF, 13A1-AG, 13A1-AH, 13A1-BF, 13A1-BG, 13A1-BH, 13A1-CF, 13A1-CG, 13A1-CH, 13A1-DF, 13A1-DG, 13A1-DH, 13A1-EF, 13A1-EG and 13A1-EH.
(FR)
L'invention concerne des anticorps, en particulier des anticorps humanisés et variants et des fragments de ceux-ci, qui se lient au TGF-β1, reconnaissant le TGF-β1 humain et murin, en particulier qui se lient préférentiellement au TGF-β1, y compris qui ne reconnaissent pas ou se lient à ΤΟΡ-β2 ou ΤΟΡ-β3. Ces anticorps sont utiles dans le diagnostic et le traitement de conditions associées à un TGF-β1 activé ou élevé, notamment le cancer, et pour la modulation des cellules immunitaires et de la réponse immunitaire, notamment la réponse immunitaire au cancer ou aux antigènes du cancer, et dans des états fibrotiques. Les anticorps anti-TGF-β1, des régions variables ou des séquences de domaines CDR de ceux-ci, et des fragments de ceux-ci peuvent aussi être utilisés dans le traitement en combinaison avec des substances chimiothérapeutiques, des modulateurs immunitaires, ou des agents anti-cancer et/ou avec d'autres anticorps ou fragments de ceux-ci. Des anticorps particuliers sont illustrés ici, comprenant les anticorps 13A1-2 A, 13A1-2 B, 13A1-2 C, 13A1-2 D, 13A1-2 E, 13A1-2 F, 13A1-2 G, 13A1-2 H, 13A1-2 I, 13A1-2 J, 13A1-AF, 13A1-AG, 13A1-AH, 13A1-BF, 13A1-BG, 13A1-BH, 13A1-CF, 13A1-CG, 13A1-CH, 13A1-DF, 13A1-DG, 13A1-DH, 13A1-EF, 13A1-EG et 13A1-EH.
Latest bibliographic data on file with the International Bureau